The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 338.00
Bid: 335.00
Ask: 338.00
Change: 25.00 (7.99%)
Spread: 3.00 (0.896%)
Open: 324.00
High: 346.00
Low: 323.00
Prev. Close: 313.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Hutchmed revenue surges, Craven House's loss widens

Wed, 28th Feb 2024 17:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Says it swings to net income of USD100.8 million for 2023, from a USD360.8 million net loss in 2022. Revenue rises 97% to USD838.0 million from USD426.4 million, with Oncology/Immunology consolidated revenue more than tripling to high end of guidance, at USD528.6 million. Includes USD280 million of an upfront payment from deal with Takeda Pharmaceutical Co Ltd. Cash balance at December 31 is USD886.3 million, up from USD631.0 million one year prior. Company does not recommend a final dividend, unchanged from 2022. Guides for USD300 million to USD400 million in Oncology/Immunology consolidated revenue in 2024.

----------

Cykel AI PLC - London-based artificial technologies firm, founded in August 2023 - Posts operating loss and pretax loss of GBP1.4 million for the period from August 22 to November 30. Cash balance at November 30 is GBP1.6 million. Says management team continues to develop and refine its task operating system, pending the expected reverse takeover by London-based special purpose acquisition company Mustang Energy PLC agreed in January.

----------

Harmony Energy Income Trust PLC - Great Britain-focused investor in commercial-scale battery energy storage systems - Net asset value at October 31 is 115.40 pence per share, down from 120.55p one year previously. Reports adjusted NAV total return of positive 1.2% for the year to October 31, following a positive 23.4% return the year before. Pretax profit falls to GBP3.1 million from GBP48.4 million. Company increases total dividend for year to 8p per share from 2p, and says it is working hard to find solutions to its current challenges, including the "deteriorated" Great British battery energy storage systems or BESS market. Acknowledges however that due to "unexpectedly low" income its dividends were paid using VAT rebates, "which the board recognises is not what shareholders expect over the long term".

----------

Craven House Capital PLC - London-based investment fund with minority shareholding in four Swedish-managed eCommerce and pharmaceutical businesses - Pretax loss for six months to November 30 is USD114,000, widening from USD72,000 the prior year. Assets at period end total USD1.16 billion, down from USD6.43 billion one year prior. Loss per share widens to 2.95 US cents from 1.86 cents. Says investees remain at 'pre-revenue' stage of business development.

----------

Malin Corp PLC - Dublin-based investor in life sciences companies - Says cash at December 31 is EUR29.3 million, compared to USD173.9 million at the same time one year prior. This has grown to EUR34.5 million at February 26 due to receipt of a contingent milestone payment from a disposal to Sanofi SA in 2021. Estimated intrinsic equity value was EUR6.56 per share at December 31 and EUR7.91 at February 26. Company says it returns EUR140.7 million of capital to shareholders throughout 2023 with a tender offer and on-market buybacks. Company also says Executive Chair Liam Daniel's role will revert to non-executive chair from Thursday.

----------

AIQ Ltd - company focused on acquiring and developing e-commerce sector businesses - Revenue for the year to October 31 falls to GBP207,209 from GBP496,296 annually. Pretax loss widens to GBP503,198 from GBP336,731. Says these results reflect challenging environment for non-fungible tokens and other blockchain technology-based products. Cash balance at October 31 is GBP135,445, down from GBP636,459 one year prior. Company says it continues to closely monitor its cash position and "is keeping all its strategic options open should the markets not turn favourable in the near-term".

----------

Renewables Infrastructure Group Ltd - investor in wind, solar and battery storage projects in Europe, advised by InfraRed Capital Partners Ltd - NAV per share at December 31 is 127.7p, down from 134.6p one year prior. Says reduction was driven by lower power price forwards and higher valuation discount rates. Says portfolio revenue for 2023 was GBP793 million, down from GBP838 million in 2022. Portfolio earnings before interest, tax, depreciation and amortisation falls to GBP610 million from GBP677 million. Dividend for 2023 totals 7.18p per share, and company is targeting a payout of 7.47p per share for 2024. Adds that the macroeconomic environment looks more "benign" this year.

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
30 Jan 2024 10:32

Hutchmed's 'Elunate' approved under new Hong Kong rules

(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tuesday, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).

Read more
30 Jan 2024 09:20

Hutchmed celebrates cancer drug approval in hometown of Hong Kong

(Alliance News) - Hutchmed (China) Ltd on Tuesday touted progress in Hong Kong, after its oral therapy for metastatic colorectal cancer received marketing approval in the city.

Read more
11 Jan 2024 11:11

Hutchmed application for thrombocytopenia treatment accepted in China

(Sharecast News) - Hutchmed China announced on Thursday that the new drug application (NDA) for sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), had been accepted for review and granted priority review by China's National Medical Products Administration (NMPA).

Read more
11 Jan 2024 10:17

TOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureau

(Alliance News) - Hutchmed Ltd on Thursday said that its novel treatment for haematological malignancies and immune diseases had been progressed to the next stage of approval by the country's national bureau for drug supervision.

Read more
21 Dec 2023 11:36

IN BRIEF: Hutchmed China renews deals with "substantial" shareholders

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Agrees with "substantial shareholder" Sinopharm Group Co Ltd to renew the Framework Sinopharm Products Supply & Purchase Agreement, effective from January 1, for three years up to and including December 31, 2026. Also agrees with HCMH to renew the HBYS Brand License Royalty agreement, also effective from January 1 and for the same duration. HCMH entered the HBYS deal in June 2021 with HWEL, a subsidiary of major shareholder CK Hutchison Holdings Ltd which holds an approximate 38.18% stake in Hutchmed.

Read more
13 Dec 2023 13:56

Hutchmed completes enrolment for fruquintinib trial

(Alliance News) - Hutchmed (China) Ltd on Wednesday said it has completed enrolment of its phase II/III trial of fruquintinib.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
9 Nov 2023 12:16

Hutchmed hails Takeda's fruquintinib approval from US for cancer form

(Alliance News) - Hutchmed (China) Ltd on Thursday announced that the Tokyo-based drug maker, Takeda Pharmaceutical Co Ltd, has received US approval of fruquintinib for a form of colorectal cancer.

Read more
29 Sep 2023 10:57

Hutchmed confirms new drug application for fruquintinib in Japan

(Sharecast News) - Hutchmed China announced on Friday that its partner Takeda has officially submitted a new drug application (NDA) for fruquintinib to the Ministry of Health, Labour and Welfare (MHLW) in Japan.

Read more
29 Sep 2023 10:12

Hutchmed notes Takeda submits fruquintinib drug application in Japan

(Alliance News) - Hutchmed (China) Ltd on Friday said Takeda Pharmaceutical Co Ltd has submitted a new drug application for cancer treatment fruquintinib to the Ministry of Health, Labour & Welfare in Japan.

Read more
14 Sep 2023 13:09

Director dealings: IPF non-exec picks up shares, Hutchmed China director linked to sale

(Sharecast News) - International Personal Finance was among the companies on the list of director purchases on Thursday after a non-executive director spent more than £18k on shares.

Read more
12 Sep 2023 11:26

Hutchmed reports progress on two oncology fronts

(Sharecast News) - Hutchmed China reported significant strides in oncology research on Tuesday, completing patient enrollment for a bridging study of tazemetostat, and announcing pivotal results for the phase 3b clinical trial of savolitinib.

Read more
12 Sep 2023 10:26

IN BRIEF: Hutchmed China finalises patient enrolment for Tazemetostat

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Completes patient enrolment for bridging phase two study in China to evaluate the efficacy of cancer drug Tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma. Tazemetostat is approved by the US Food & Drug Administration for the treatment of advanced epithelioid sarcoma and R/R FL.

Read more
29 Aug 2023 13:38

Hutchmed tumour therapy candidate gets breakthrough designation

(Sharecast News) - Pharmaceuticals developer Hutchmed China announced on Tuesday that the Center for Drug Evaluation of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to its investigational drug savolitinib.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.